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Multidrug-resistant organisms are an increasing threat to health-
care worldwide. Treatment options for these so-called ‘superbugs’ 
are limited, with very few new antimicrobials currently in devel-
opment.
One such organism is vancomycin-resistant Enterococcus (VRE). 
This organism has been detected worldwide in hospitalised adult 
and paediatric patients since the first description in 1986.[1] Infection 
and/or colonisation with VRE has been described in patients who are 
potentially immunosuppressed, especially those with malignancies, 
solid organ transplant recipients, those with chronic renal disease 
requiring haemodialysis, neonates and those requiring long-term 
ventilation.[2,3]
Resistance to vancomycin occurs in E. faecium and E. faecalis 
species primarily owing to the vanA and vanB resistance genes. 
The first clinical reports of VRE in South African (SA) adults 
appeared in 1997 and there is currently a paucity of SA paediatric 
studies describing the incidence of VRE or outbreaks of this 
organism.[4]
We report on the first identification of VRE infections in the 
paediatric oncology ward at a tertiary-level paediatric hospital in 
Cape Town, SA, over two time periods in 2013.
Methods
Identification
The first two VRE organisms causing bloodstream infections (VRE-
BSI) were isolated from blood culture specimens of two patients, 
2  days apart, in February 2013. Seven and 9 months later, in 
September and November 2013, respectively, VRE was once again 
isolated from blood culture specimens in an additional two patients. 
Following the two time periods, patient hospital records were 
accessed to identify possible risk factors associated with acquiring 
VRE-BSI in this setting. Patient records were anonymised and 
de-identified prior to analysis. Routine screening is not carried out 
for drug-resistant organisms on admission to the hospital.
Setting
The haematology/oncology unit at Red Cross War Memorial 
Children’s Hospital (RCWMCH) in Cape Town, SA, is a 17-bed 
unit with a high-care unit and isolation cubicles. There is a daily 
outpatient service and a day ward in the area adjoining the main 
ward. It serves as a referral centre for children with haematological 
and solid organ malignancies from other local or distant hospitals 
in the country. Children are admitted from home or long-term 
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but one. PFGE and MLST results showed a degree of genetic relatedness between certain isolates obtained from rectal swab and blood 
culture samples, suggesting possible patient-to-patient transmission or persistence of the isolates in the unit.
Conclusion. Strict infection control practices are necessary to prevent infection and transmission of resistant organisms among vulnerable 
patients.
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care facilities. The unit has approximately 
2 000 admissions, with an additional 5 500 
outpatient visits, per year
Surveillance
Following identification of the first two 
VRE infections, collaboration between the 
paediatric oncologists, microbiologists, 
paediatric infectious diseases physicians, 
infection control nursing staff and ward 
nursing staff was instituted to limit further 
spread by improving infection prevention 
and control measures. Active surveillance 
for rectal colonisation with VRE of patients 
in the ward and discharged patients who had 
prior contact with the index cases was carried 
out by means of culture and sensitivity 
testing using rectal swabs or stool samples. If 
rectal swabs were negative for VRE at initial 
screening, a repeat was taken at 1 - 2-weekly 
intervals until three consecutive negative 
swabs were documented.[5]
Infection control
Infected patients were isolated in single 
cubicles until discharged. Contact precau-
tions during patient interaction were insti-
tuted for patients, family and staff members. 
Colonised patients were cohorted until 
discharged. Medical records were marked 
to ensure isolation, and re-screening by 
rectal swab occurred during subsequent 
admissions. Staff and parents were re- 
educated regarding correct handwashing 
tech nique, use of alcohol hand sanitiser and 
contact precautions.
Microbiological methods
All microbiological and molecular analyses 
were conducted by the National Health 
Laboratory Service at Groote Schuur Hospital 
and the Division of Medical Microbiology, 
University of Cape Town (UCT), SA. 
Surveillance specimens were plated directly 
onto selective media (colistin nalidixic blood 
agar impregnated with a 30 µg vancomycin 
disc) and incubated for up to 48 hours. 
Identification and susceptibility testing of 
colonies growing within the inhibition zone 
close to the vancomycin disc were performed 
using the Vitek 2 GP and AST-P603 cards 
respectively, with interpretation according to 
contemporary Clinical Laboratory Standards 
Institute criteria.[6] Vancomycin minimum 
inhibitory concentrations (MICs) were 
determined using the Etest method.[6] MICs 
≥32 μg/mL were considered resistant.
Isolates were characterised genotypically 
with the Hain Genotype Enterococcus line 
probe assay according to the manufacturer’s 
instructions, or in-house polymerase chain 
reaction (PCR) assay as described below.
In-house PCR assay for genotyping 
enterococci
All vancomycin-resistant isolates were 
screened for the presence of the vanco-
mycin resistance genes vanA, B and 
C1, 2, 3 with DNA purified using the 
ZR  Fungal/Bacterial DNA MiniPrep kit 
(Zymo Research, USA) according to 
the manufacturer’s instructions.[7] PCR 
reactions (25 µL) were carried out using 
GoTaq Flexi (Promega, USA) with an 
annealing temperature of 60°C, for 35 
cycles, in a GeneAmp 9700 thermocycler. 
PCR amplicons were visualised by agarose 
gel electrophoresis and ethidium bromide 
staining. Amplicons were confirmed with 
DNA sequence analysis (Inqaba Biotech, 
SA) and BLASTN (http://blast.ncbi.nlm.
nih.gov/Blast) comparisons.[8]
Pulsed-field gel electrophoresis
Isolates of interest were analysed using 
pulsed-field gel electrophor esis (PFGE), 
as described by the Centers for Disease 
Control and Prevention, with the following 
changes: cultures were grown on BHI 
medium, at 37°C, aerobically overnight, 
and cell densities were standardised to an 
OD610nm≈1.0, using a spectrophotometer 
(BioDrop, UK).[9] Cells were embedded in 
a 1.0% SeaKem Gold agarose gel (Lonza, 
Switzerland) and were digested for 2 hours 
at 25°C using SmaI (Thermo Scientific, 
USA) restriction endonuclease and ApaI 
as a secondary enzyme (2 hours at 37°C). 
Digested plugs were electrophoresed 
through a 1.0% SeaKem Gold agarose gel 
(Lonza, Switzerland) in 0.5% TBE buffer 
(14 °C), using the Gene Navigator (Amer-
sham Biosciences, UK) at 200 V, with a 
ramped switching time of 3.5 - 23.5 
seconds over 18 hours. The resultant gel 
was visualised using ethidium bromide 
staining, and the gel image analysed and 
dendrogram generated using Gel Compare 
II (BioNumerics v.6.6, Applied-Maths, 
USA), with an optimisation of 1.0 and a 
band tolerance of 1.5. The dendrogram 
was constructed using the pairwise average 
from the SmaI and ApaI results, with the 
UPGMA (unweighted pair group method 
with arithmetical mean) method and branch 
quality was calculated using the cophenetic 
correlation. E. faecalis ATCC 51299 was 
used as a control and for normalisation.
Multilocus sequence typing
Cellular DNA was extracted from selected 
isolates and PCR was carried out as 
described above using the conditions 
described by Homan et al.[10] Amplicons 
were sequenced bidirectionally (Inqaba T
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Biotech, SA) and the consensus sequences uploaded and typed at 
using an E. faecium multilocus sequence typing (MLST) database.[11]
Ethical considerations
Ethics approval to perform this study was obtained from the Human 
Research Ethics Committee, UCT (HREC Ref. No. 022/2015).
Results
Description of the infection
The ward had 100% occupancy during the months of VRE isolation. 
All four BSI patients were long-term residents in the unit at the time 
of the infections and were therefore classified as hospital-acquired 
infections. Patients 2 and 4 were transferred from a referral hospital 
outside Cape Town, where VRE had previously been isolated. Neither 
of these patients was screened prior to their transfer to RCWMCH. 
The clinical features and underlying risk factors at the time of BSI 
were similar in all four identified patients (Table 1). Three of the 
infected patients cultured vancomycin-sensitive E. faecium (VSE) 
isolates from blood in the week preceding the VRE-BSI. All four 
were treated with vancomycin in the week prior to the the VRE-BSI, 
and three had suboptimal vancomycin trough drug levels (≤15 µg/
mL). Patient 2 had renal impairment which resulted in the increased 
trough levels of vancomycin. Central venous catheters were removed 
from all infected patients after detection of the VRE-BSI. Infected 
patients were treated with intravenous linezolid. Patients 2 and 3 had 
protracted periods of illness prior to the BSI and demised from a new 
Gram-negative BSI and typhilitis following the VRE-BSI, respectively.
Surveillance
Two of 29 (6.9%) patients who were residing in the ward or recently 
discharged were screened (as identified above) by rectal swab 
for VRE during February and March 2013 and a further 6 of 26 
(23.1%) patients screened between September and October 2013 
were positive for VRE. Patient 4 screened positive on rectal swab and 
subsequently progressed to develop a VRE-BSI a week later. Although 
the overall number of patients colonised with VRE was 14.5% (8/55), 
surveillance swabbing was not routinely performed between March 
and September, and the true prevalence was therefore not established. 
There were, however, no cases of clinical disease due to VRE 
documented between March and September 2013. Environmental 
screening for VRE was not conducted in the unit.
Microbiology
All but one isolate obtained (surveillance and infection) was 
identified as E. faecium, using the Vitek 2 system. The additional 
isolate obtained on rectal swab was identified as E. faecalis based 
on vancomycin sensitivity testing. Vancomycin MICs on Etest were 
≥256  µg/mL for the four BSI isolates, confirming high-level resis-
tance of E. faecium to vancomycin.[8]
Molecular testing
PCR analysis detected the vanA gene in all of the VRE isolates 
obtained from infected patients and all but one of the VRE screening 
isolates. This isolate tested positive for the vanB gene. PFGE analysis 
of these isolates showed that there was genetic diversity among the 
isolates, which was not indicative of an outbreak. There was, however, 
a high level of genetic relatedness (>85% confidence interval) 
between some of the strains tested (Fig.  1). The E. faecalis isolate 
obtained during the February - March surveillance screening did not 
undergo any further molecular typing, even though the vanA gene 
was detected on PCR.
Patients 1 and 2, who were considered to be the index cases of 
a suspected outbreak, had isolates which shared 92.5% homology, 
indicating a strong possibility of patient-to-patient transmission of 
the same clone. This result was unusual since the patient 2 isolate 
in question (No. 13) was obtained from a rectal swab and the isolate 
obtained from the blood culture of Patient 2 (No. 3) did not show 
strong homology with each other.
85% condence interval 
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07  Patient 1  Blood  ST817
05  Patient 1  Blood  ST817
30  Patient 3  Blood  ST18
62  Patient 4  Blood  ST80
03  Patient 2  Blood  ST817
13  Patient 2  Swab  ST817
33  Patient 5  Swab
34  Patient 6  Swab  ST117
14  Patient 7  Tissue  ST262
37  Patient 8  Swab 
36  Patient 9  Swab  ST203
35  Patient 10  Swab
39  Patient 4  Swab  ST80
15  Patient 11  Swab
57  ATCC  51299
92.5
97.2
91.4 100
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33.3
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12.4
61.1
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Fig. 1. Dendrogram of isolates obtained during investigation. Shaded bars indicate branch error flags and unshaded values indicate the levels of relatedness. 
Patients 1 - 4 represent the patients with VRE-BSIs. Patients 5, 6 and 8 - 11 indicate the patients colonised with VRE (patient 11 in February and March, 
and patients 5, 6, 8, 9 and 10 in September and October; patient 7 was not a haematology/oncology patient). The specimen types and MLST sequence types 
are indicated in the last two columns, respectively.
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The second isolate from patient 1 (No. 5), obtained from a blood 
culture, shared 97.2% homology with the blood culture isolate from 
patient 3 (No. 30). Isolate No. 30 was faintly positive for the vanA 
gene on PCR and susceptible to vancomycin. Previous isolates from 
this patient produced strong positive PCR results and high levels of 
vancomycin resistance. None of the resistant isolates from patient 3 
showed significant homology to the sensitive isolate or to any of the 
other strains tested (data not shown). The two isolates obtained from 
blood in patient 1 (Nos 5 and 7), however, shared very little genetic 
homology. These data indicated the possibility of a rapid rate of strain 
variation, even within the same patient, in this setting. The two isolates 
from patient 4 (Nos 39 and 62) shared only 61.1% homology with each 
other and very low homology with any of the other strains tested.
There were five screening strains, in two clusters, that shared 
high genetic homology with each other. Cluster 1 (91.4% homology) 
comprised patients 5, 6 and 7 and cluster 2 (87.8% homology) 
comprised patients 8 and 9. Patient 7 (No. 14) in cluster 1 was PCR-
positive for the vanB gene, but still shared high homology with the 
other two isolates, which were both vanA-positive. This patient had 
no prior contact with the haematology/oncology unit. The isolate 
was obtained from autopsy of the lung tissue and was probably a 
contaminant and not a comorbidity. Cluster 2 comprised two isolates 
that were obtained from different patients on the same day. These 
results indicated the possibility of spread within the hospital.
MLST analysis revealed that the four isolates from patients 1 and 
2 (Nos 3, 5, 7 and 13) all shared the same sequence type (ST817). 
Even though these isolates do not share significant homology in the 
dendrogram, it strengthens the assumption that these two patients 
probably had patient-to-patient transmission of the same clone that 
may have changed over time. The two isolates from patient 4 (Nos 39 
and 62) that shared 61.1% homology also shared the same sequence 
type (ST80). They are single-locus variants of ST817, with a single 
polymorphism in the adk gene (189G>A).
Infection control
A multidisciplinary approach was instituted to prevent further 
spread of the organism within the oncology unit. Infection control 
staff assisted with ensuring that infected patients were isolated and 
all ward staff members were educated about contact precautions. 
Colonised patients were cohorted in the multi-bed cubicles for the 
duration of their hospital stay. Discharged patients were identified to 
determine who required screening on their next visit. 
The ward was closed off to all new admissions until all colonised 
or infected patients were discharged. Once all colonised or infected 
patients were discharged, the ward was comprehensively cleaned.
Following the first two cases of VRE-BSI, antibiotic stewardship 
ward rounds were instituted in the oncology unit, to improve 
antibiotic management including optimisation of vancomycin 
dosing. All patients who required transfer from other hospitals to 
the oncology unit at RCWMCH, where VRE had previously been 
documented, were screened for VRE by rectal swab prior to transfer.
Discussion
This is the first documented report of VRE infection in children in 
SA. A prevalence study in SA found 10.9% (20/184) of screening rectal 
swabs in at-risk patients to be positive for enterococal isolates. [12] This 
study also showed clonal spread of the vanA and vanB genotypes 
in different hospitals, as well as persistence of the vanA carrying 
strain over time. The vanA genotype has been commonly isolated in 
previous outbreak settings.[2,3]
Even though the PFGE results indicated overall genetic diversity 
between the isolates analysed, there was a degree of genetic relatedness 
between specific blood and rectal swab samples on both PFGE and 
MLST analysis. These results may suggest possible patient-to-patient 
transfer of VRE or persistence of the organism in the haematology/
oncology unit between the two time periods described. Patient 4 
was infected by a molecularly distinct, unrelated isolate, possibly 
before transfer to RCWMCH at a referral hospital where VRE had 
previously been isolated. The identified sequence type (ST80) along 
with ST203 (No. 36) and ST18 (No. 30) have previously been assigned 
to clonal complexes (CC) CC117, CC78, and CC17, respectively, 
which are known to form part of the CC17 meroclone. The CC17 
meroclone has been described as highly diverse with documented 
worldwide spread.[13] These data again highlight the high levels of 
strain variation observed in this setting.
The purpose of screening is to identify carriers during outbreaks, 
and in non-outbreak settings to prevent transmission, especially 
to vulnerable patient groups.[14] Active screening outside outbreak 
settings can be a costly exercise and especially difficult in resource-
constrained health systems. Screening in children has revealed low 
rates of colonisation. Active screening of paediatric patients found 
that 3.4% (41/1 211) were colonised with VRE, of whom 39/41 
(95.1%) had an underlying chronic disease.[15]
Risk factors for acquiring a BSI or colonisation with this 
highly resistant organism have been investigated. There are few 
paediatric studies regarding the risk factors for acquiring VRE. 
Acquisition of VRE has been associated with previous treatment 
with broad-spectrum antimicrobials, especially third-generation 
cepholosporins, and the carbapenems, as well as immunosuppression 
with antineoplastic chemotherapy, haemotology/oncology and renal 
patients, increased length of stay in hospital, and a younger age 
in children.[13] Progression from VRE colonisation to VRE-BSI 
in patients was associated with admission from a long-term care 
facility, infection of an additional body site other than blood and 
receipt of vancomycin.[16] In contrast, Pentima et al.[17] found that 
VRE-BSI was independent of patient vancomycin exposure. Risk 
factors in our patient cohort are similar to those described. All the 
patients with VRE-BSI had an underlying haematological condition 
requiring immunosuppressive therapy for treatment and received 
vancomycin for treating presumed Gram-positive infections. Central 
venous catheters were present in all four infected patients and, 
although not found to be a risk factor in the studies mentioned, could 
represent a possible clinical source for BSI. The colonised patients, 
although not clinically ill at the time, also had similar risk factors: 
all were exposed to vancomycin at some period during their illness 
and had underlying immunosuppression in the period preceding 
the screening. As mentioned, only one of the colonised patients 
progressed to developing bacteraemia with VRE.
Treatment for this resistant organism is limited to the use of 
linezolid and daptomycin. In SA, daptomycin is difficult to access in 
the public health system. Linezolid, an oxazolidinone antibacterial 
agent, has proven to be effective in the treatment of the glycopeptide-
resistant Enterococcus, as well as methicillin-resistant Staphylococcus 
aureus and penicillin-resistant Streptococcus pneumoniae in children, 
and was used to treat the infected patients in this study.[18]
Study limitations
The limitations of this study include lack of a case-control group to 
conclusively identify risk factors associated with VRE acquisition in 
our patients, and an insufficient sample size to ascertain whether an 
outbreak had occurred and to determine the definitive phylogenetic 
relationships of the VRE strains present in this setting. Owing 
to financial constraints, no active surveillance was possible after 
October 2013, so whether or not further transmission occurred and 
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the duration of colonisation with VRE were not established. However, 
no further VRE cases were reported in the oncology unit or the 
hospital after November 2013.
Conclusion
In conclusion, effective infection control practices are important 
to limit or prevent transmission of multidrug-resistant pathogens 
among vulnerable hospitalised populations. Furthermore, the 
emergence of glycopeptide-resistant enterococci has emphasised the 
importance of antibiotic stewardship in the haematology/oncology 
unit and the institution overall.
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